Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:57 p.m. and Nov. 22, 2024, 7:57 p.m. from: Cro (Contract Research Organization) Business.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

Document Date: Nov. 20, 2024, 2:05 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Buyer: Document Extract: QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group.
Document Source: https://www.businesswire.com/news/home/20241119268143/en/QuidelOrtho-Corporation-Announces-Pricing-of-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group (archive.org page / archive.org listing)


QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group

Document Date: Nov. 20, 2024, 2:05 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Buyer: Document Extract: QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") , a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company's common stock ("Common Stock") .
Document Source: https://www.businesswire.com/news/home/20241119268143/en/QuidelOrtho-Corporation-Announces-Pricing-of-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group (archive.org page / archive.org listing)


QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

Document Date: Nov. 19, 2024, 9:54 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Buyer: Document Extract: QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") , a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company's common stock ("Common Stock") .
Document Source: https://www.businesswire.com/news/home/20241112164377/en/QuidelOrtho-Corporation-Announces-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group (archive.org page / archive.org listing)


QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group

Document Date: Nov. 19, 2024, 9:54 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Ipo / Region: United States
Vendor: Buyer: Document Extract: QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group.
Document Source: https://www.businesswire.com/news/home/20241112164377/en/QuidelOrtho-Corporation-Announces-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group (archive.org page / archive.org listing)


Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity

Document Date: Nov. 21, 2024, 1 p.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: This work enabled Metsera to recently initiate a randomized 16-week Phase II trial of MET-097i. In addition to clinical conduct, Altasciences supported Metsera with its Proactive Drug Development solution, including nonclinical, bioanalysis, CRO and program management services for several additional therapeutic candidates. Over the past six months, Altasciences has completed nonclinical work for MET-233i, as well as MET-002, an oral GLP-1 receptor agonist peptide, which has proven instrumental in allowing Metsera to begin clinical trials for both programs this year. " Congratulations to Metsera on reaching this significant milestone in the development of MET-097i ," said Ingrid Holmes, Vice President of Global Clinical Operations at Altasciences. " Metsera is a highly valued partner of Altasciences, and we are proud to have contributed to this program aimed at helping individuals struggling with obesity-related illnesses ."
Document Source: https://www.businesswire.com/news/home/20241121694414/en/Altasciences-Supports-Metsera-in-Their-Early-Stage-Clinical-Trials-for-Obesity (archive.org page / archive.org listing)


Canadian CRO Innovaderm looks to expand in Europe with new vice president

Document Date: Nov. 19, 2024, 3:50 p.m. / Source: Fierce Biotech
Activity Class: RoleActivity / Type: Starting / Region: Canada
Role: Person: Organization: Document Extract: Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as executive vice president of European operations and strategy.
Document Source: https://www.fiercebiotech.com/cro/canadian-cro-innovaderm-looks-expand-europe-new-vice-president (archive.org page / archive.org listing)


Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director

Document Date: Nov. 21, 2024, 12:04 p.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) - Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985096/0/en/Velocity-targets-Latin-America-expansion-with-the-appointment-of-Renata-Berardocco-as-LATAM-Managing-Director.html (archive.org page / archive.org listing)


Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director

Document Date: Nov. 21, 2024, 12:04 p.m. / Source: GlobeNewswire
Activity Class: RoleActivity / Type: Starting
Role: Person: Organization: Document Extract: Velocity targets Latin America expansion with the appointment of Renata Berardocco as LATAM Managing Director.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985096/0/en/Velocity-targets-Latin-America-expansion-with-the-appointment-of-Renata-Berardocco-as-LATAM-Managing-Director.html (archive.org page / archive.org listing)


American Brain Tumor Association Names New President & Chief Executive Officer

Document Date: Nov. 18, 2024, 4:08 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Starting / Region: Chicago
Role: Person: Organization: Document Extract: CHICAGO, Nov. 18, 2024 /PRNewswire/ - The American Brain Tumor Association (ABTA) today announced that the organization's board of directors has appointed Kelly Sitkin as ABTA's next President & Chief Executive Officer, effective February 1, 2025.
Document Source: https://www.prnewswire.com/news-releases/american-brain-tumor-association-names-new-president--chief-executive-officer-302308729.html (archive.org page / archive.org listing)


American Brain Tumor Association Names New President & Chief Executive Officer

Document Date: Nov. 18, 2024, 4:08 p.m. / Source: PR Newswire
Activity Class: RoleActivity / Type: Finishing / Region: Chicago
Role: Person: Organization: Document Extract: CHICAGO, Nov. 18, 2024 /PRNewswire/ - The American Brain Tumor Association (ABTA) today announced that the organization's board of directors has appointed Kelly Sitkin as ABTA's next President & Chief Executive Officer, effective February 1, 2025.
Document Source: https://www.prnewswire.com/news-releases/american-brain-tumor-association-names-new-president--chief-executive-officer-302308729.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.